Subscribe To
KALA / Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment
KALA News
By Zacks Investment Research
April 13, 2023
KALA Up on Fast Track Designation to Lead Ocular Candidate
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects. more_horizontal
By Zacks Investment Research
March 24, 2023
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not prove more_horizontal
By GlobeNewsWire
March 8, 2023
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to more_horizontal
By Zacks Investment Research
March 6, 2023
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6. more_horizontal
By Zacks Investment Research
February 22, 2023
Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know
Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session. more_horizontal
By Seeking Alpha
January 19, 2023
Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform
FDA Accepted IND Filing for the company to initiate a phase 2b study using KPI-012 for the treatment of patients with the persistent corneal epithelia more_horizontal
By MarketBeat
January 11, 2023
Kala Pharmaceuticals Up 400% In The Past Month, What's Next?
Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom. more_horizontal
By Market Watch
December 30, 2022
Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the bioph more_horizontal